{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:09:09Z","timestamp":1788815349259,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijgc.2026.104875","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:07:09Z","timestamp":1783919229000},"page":"104875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Best original research presented at the 27th European Congress on Gynaecological Oncology: best of ESGO 2026"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7613-8354","authenticated-orcid":false,"given":"Houssein","family":"El Hajj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9769-7240","authenticated-orcid":false,"given":"Alexander","family":"Shushkevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2539-3894","authenticated-orcid":false,"given":"Joanna","family":"Kacperczyk-Bartnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5134-4466","authenticated-orcid":false,"given":"Andrej","family":"Cokan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0956-1050","authenticated-orcid":false,"given":"Ilker","family":"Kahramanoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1574-6572","authenticated-orcid":false,"given":"Tibor Andrea","family":"Zwimpfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9535-5821","authenticated-orcid":false,"given":"Richard","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Strojna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-0627","authenticated-orcid":false,"given":"David","family":"Viveros-Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1727-904X","authenticated-orcid":false,"given":"Nicol\u00f2","family":"Bizzarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4401-3084","authenticated-orcid":false,"given":"Martina Aida","family":"Angeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khayal","family":"Gasimli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0499-5722","authenticated-orcid":false,"given":"Ilker","family":"Selcuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5501-1936","authenticated-orcid":false,"given":"Giuseppe","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-3539","authenticated-orcid":false,"given":"Jonathan","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Heinzelmann-Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2026.104608","article-title":"Simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: an exploratory analysis from the GCIG\/CCTG CX.5\/SHAPE trial","volume":"36","author":"Kim","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2026.104607","article-title":"Quality of life and lower-limb lymphoedema after sentinel lymph node biopsy versus pelvic lymphadenectomy in early-stage cervical cancer: results from the prospective multicentre SENTIX study (CEEGOG-CX01; ENGOT-CX2; NCT02494063)","volume":"36","author":"Kocian","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104875_bib3","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/s43018-025-01016-y","article-title":"Sentinel lymph node biopsy without systematic pelvic lymphadenectomy in females with early-stage cervical cancer: final outcome of the SENTIX prospective, single-arm, noninferiority, international trial","volume":"6","author":"Cibula","year":"2025","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.104432","article-title":"Sentine node positive POLE-mutated endometrial cancer","volume":"36","author":"Bogani","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104875_bib5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ijgc-2023-004289","article-title":"Improving Endometrial cancer assessment by combining the new techniqUe of GENomic profiling with surgical Extra uterIne disEase assessment (EUGENIE)","volume":"33","author":"Kasius","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2026.104574","article-title":"Improving endometrial cancer assessment by combining the new technique of genomic profiling with surgical extra uterine disease assessment (EUGENIE)","volume":"36","author":"Trozzi","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.104433","article-title":"A multicenter retrospective study comparing one step nucleid amplification (OSNA) and conventional ultrastaging for sentinel lymph node assessment in early-stage endometrial cancer","volume":"36","author":"N\u00fa\u00f1ez","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104875_bib8","doi-asserted-by":"crossref","first-page":"9080","DOI":"10.1245\/s10434-025-17836-2","article-title":"The MULTISENT study: a multicenter study on the detection rate of sentinel lymph node mapping in endometrial cancer across Spain","volume":"32","author":"G\u00f3mez-Hidalgo","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.104435","article-title":"Morbidity reduction using sentinel lymph node biopsy in intermediate and high-risk early-stage endometrial cancer: a prospective multicenter trial (sentirad)","volume":"36","author":"Bresson","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.104436","article-title":"POLARIX: POLE-mutation analysis by rapid image-based screening in endometrial cancer","volume":"36","author":"Van Den Berg","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102890","article-title":"No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinomas","volume":"36","author":"Wakkerman","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102914","article-title":"Beyond recurrence site: molecular profile determines prognosis after relapse in endometrial cancer","volume":"36","author":"Aznar","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102913","article-title":"Tumour immune microenvironment signatures by RNA profiling predict prognosis in dMMR endometrial cancer","volume":"36","author":"Arozamena","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104875_bib14","doi-asserted-by":"crossref","first-page":"108.e1","DOI":"10.1016\/j.ajog.2024.07.027","article-title":"A clinical ultrasound algorithm to identify uterine sarcoma and smooth muscle tumors of uncertain malignant potential in patients with myometrial lesions: the MYometrial Lesion UltrasouNd and mRi study","volume":"232","author":"Ciccarone","year":"2025","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102920","article-title":"Integration of inflammatory markers and ultrasound features to improve preoperative diagnosis in high-risk patients with uterine mesenchymal tumors: the IMPRINT study","volume":"36","author":"Bruno","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102898","article-title":"The European society of gynaecological oncology (ESGO) consensus statements on opportunistic salpingectomy for the prevention of epithelial ovarian cancer","volume":"36","author":"Piek","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102918","article-title":"Ovarian cancer incidence according to subtype of endometriosis: a population based study","volume":"36","author":"Uffing","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104875_bib18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ygyno.2021.07.006","article-title":"Increased incidence of ovarian cancer in both endometriosis and adenomyosis","volume":"162","author":"Hermens","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102919","article-title":"Risk of ovarian cancer in women with a pathogenic or likely pathogenic variant in NBN in 38,337 women: a systematic review and meta-analysis","volume":"36","author":"Ganesan","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102912","article-title":"Ultrasound features of malignant transformation of deep endometriosis: preliminary results from a multicentre descriptive study","volume":"36","author":"Panizzolo","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104875_bib21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"9990","key":"10.1016\/j.ijgc.2026.104875_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104875_bib23","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib24","article-title":"Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer","volume":"2","author":"Shawky","year":"2025","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.ijgc.2026.104875_bib25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2020.02.020","article-title":"Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomised trial","volume":"130","author":"Onda","year":"2020","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102895","article-title":"TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 \/ AGO-OVAR OP7)","volume":"36","author":"Mosgaard","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 2","key":"10.1016\/j.ijgc.2026.104875_bib27","first-page":"S712","article-title":"1064O ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III\u2013IV epithelial ovarian cancer (EOC): final overall survival (OS) analysis","volume":"36","author":"Clamp","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102893","article-title":"ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III\u2013IV epithelial ovarian cancer: final overall survival (OS) analysis","volume":"36","author":"Clamp","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102892","article-title":"Impact of KELIM chemosensitivity and interval cytoreduction on survival outcomes from neoadjuvant weekly dose-dense paclitaxel +\/\u2212 bevacizumab : pooled analysis of ICON8 and ICON8B phase III trials","volume":"36","author":"You","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104875_bib30","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(22)00283-2","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial","volume":"23","author":"Clamp","year":"2022","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104875_bib31","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the Phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102894","article-title":"Impact of HIPEC on survival and morbidity after interval debulking surgery (R0) in ECOG 0\u20131 patients with advanced ovarian cancer: analysis of the international SUROVA study","volume":"36","author":"Manzour","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.104430","article-title":"SUROVA predictive score for postoperative complications after primary cytoreductive surgery in advanced ovarian cancer","volume":"36","author":"Chacon","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104875_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102732","article-title":"Pembrolizumab VS placebo plus paclitaxel \u00b1 bevacizumab for platinum-resistant recurrent ovarian cancer: results from the PHASE 3 ENGOT-OV65\/KEYNOTE-B96 study","volume":"35","author":"Colombo","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102891","article-title":"Pembrolizumab vs placebo plus weekly paclitaxel \u00b1 bevacizumab in platinum-resistant recurrent ovarian cancer: final analysis results from the randomized double-blind phase 3 ENGOT-ov65\/KEYNOTE-B96 study","volume":"36","author":"Colombo","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2026.104568","article-title":"Patient-reported outcomes from ENGOT-ov65\/KEYNOTE-B96: a phase 3, randomized, double-blind study of pembrolizumab vs placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer","volume":"36","author":"Zsiros","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"10496","key":"10.1016\/j.ijgc.2026.104875_bib37","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.104426","article-title":"Rosella (GOG3073, engotov72, APGOT-OV10): a phase 3 study of relacorilant + nab-paclitaxel in patients with platinum-resistant ovarian cancer","volume":"36","author":"Lorusso","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102906","article-title":"Results from the first-in-human phase 1 study of LY4170156, a folate receptor alpha-targeting antibody drug conjugate, in ovarian cancer patients previously exposed to antibody drug conjugate therapy","volume":"36","author":"Madariaga","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102907","article-title":"The impact of clinical sample collection timing on FR\u03b1 expression and mirvetuximab soravtansine patient outcomes in the MIRASOL (GOG 3045\/ENGOT-ov55) trial","volume":"36","author":"Cecere","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102917","article-title":"Stereotactic radiotherapy versus secondary cytoreduction in the management of first recurrence during and after PARP inhibitor maintenance in ovarian cancer: a propensity matched analysis","volume":"36","author":"Loverro","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102916","article-title":"The surgery in recurrent ovarian cancer research consortium (suROC-CON): value of secondary cytoreduction for recurrent epithelial ovarian cancer in a multicenter, high surgical quality setting","volume":"36","author":"Tsibulak","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104875_bib43","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104875_bib44","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.104429","article-title":"RECOVER (recurrence ovarian cancer real life): a MITO (multicenter Italian trials in ovarian cancer) real-world study comparing cytoreductive surgery and chemotherapy in platinum-sensitive recurrent ovarian cancer with known BRCA status","volume":"36","author":"Rosati","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104875_bib46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2015.09.077","article-title":"Sentinel nodes in vulvar cancer: long-term follow-up of the Groningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I","volume":"140","author":"Te Grootenhuis","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"32","key":"10.1016\/j.ijgc.2026.104875_bib47","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.21.00006","article-title":"Radiotherapy versus inguinofemoral lymphadenectomy as treatment for vulvar cancer patients with micrometastases in the sentinel node: results of GROINSS-V II","volume":"39","author":"Oonk","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.104412","article-title":"Long-term follow-up of the groningen international studies on sentinel nodes in vulvar cancer (GROINSS-V I & II): outcomes for patients with sentinel node metastases","volume":"36","author":"Van Der Kolk","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104875_bib49","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/AOG.0000000000006051","article-title":"Complications and recurrence after pelvic exenteration for gynecologic malignancies: survival analysis from the COREPEX study","volume":"146","author":"Bizzarri","year":"2025","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.104413","article-title":"Pelvic exenteration for vulvar cancer: survival and morbidity outcomes from the COREPEX (complications and recurrence after pelvic exenteration) project","volume":"36","author":"Zach","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104875_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2026.111468","article-title":"Pelvic exenteration for vulvar cancer: contemporary outcomes from a multinational cohort study","volume":"52","author":"Zach","year":"2026","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104875_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102915","article-title":"Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study - RICE study","volume":"36","author":"Kabirian","year":"2026","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:46:50Z","timestamp":1788814010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26004068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1048891X26004068"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104875","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Best original research presented at the 27th European Congress on Gynaecological Oncology: best of ESGO 2026","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104875"}}